The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...

If your constipation lasts for more than three days, speak with your doctor about options to help. You might need to add a ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduc ...

Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.